Recurrent Cervical Cancer

Also known as: Cervical cancer recurrent / Carcinoma uterine cervix recurrent / Cervical carcinoma recurrent / Ca cervix recurrent / Carcinoma uterine cerix recurrent / Cervix uteri cancer recurrent / Cervix carcinoma recurrent / Carcinoma cervix recurrent

DrugDrug NameDrug Description
DB00112BevacizumabA recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.
DB00361VinorelbineVinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) [L1998]. It was initially approved in the USA in 1990's for the treatment of NSCLC [L2010]. It is a third-generation vinca alkaloid. The introduction of third-generation drugs (vinorelbine, gemcitabine, taxanes) in platinum combination improved survival of patients with advanced NSCLC, with very similar results from the various drugs. Treatment toxicities are considerable in the combination treatment setting [A32347]. A study was done on the clearance rate of vinorelbine on individuals with various single polymorphonuclear mutations. It was found that there was 4.3-fold variation in vinorelbine clearance across the cohort, suggesting a strong influence of genetics on the clearance of this drug [L2002].
DrugDrug NamePhaseStatusCount
DB019337-Hydroxystaurosporine1Completed1
DB00958Carboplatin1Completed2
DB00515Cisplatin1Completed1
DB00530Erlotinib1Completed1
DB00441Gemcitabine1Completed1
DB00762Irinotecan1Completed1
DB01229Paclitaxel1Completed1
DB06287Temsirolimus1Completed1
DB00072Trastuzumab1Completed1
DB11940Triapine1Completed1
DB00361Vinorelbine1Completed1
DB00112Bevacizumab2Completed1
DB00515Cisplatin2Completed1
DB04940Eribulin2Active Not Recruiting1
DB08871Eribulin2Active Not Recruiting1
DB00530Erlotinib2Completed1
DB12117Mitometh2Completed1
DB01268Sunitinib2Completed1